NeoGenomics Appoints New CEO, Dr. Mark Mallon
Ticker: NEO · Form: 8-K · Filed: Apr 18, 2024 · CIK: 1077183
Sentiment: neutral
Topics: leadership-change, executive-appointment, management-transition
TL;DR
New CEO Mark Mallon takes over NeoGenomics, replacing Jeff Miller.
AI Summary
On April 15, 2024, NeoGenomics Inc. announced the appointment of Dr. Mark Mallon as Chief Executive Officer and a member of the Board of Directors, effective immediately. Dr. Mallon previously served as CEO of Adaptive Biotechnologies. The company also announced the departure of its former CEO, Dr. Jeffrey Miller, and the appointment of Dr. Steven B. Johnson as Interim Chief Medical Officer.
Why It Matters
The appointment of a new CEO, especially one with prior experience leading a biotech company, can signal a strategic shift or renewed focus for NeoGenomics, potentially impacting its future growth and market position.
Risk Assessment
Risk Level: medium — Leadership changes at the CEO level can introduce uncertainty regarding strategic direction and operational execution, which may affect investor confidence.
Key Players & Entities
- NeoGenomics Inc. (company) — Registrant
- Dr. Mark Mallon (person) — Appointed CEO and Board Member
- Dr. Jeffrey Miller (person) — Departing CEO
- Dr. Steven B. Johnson (person) — Appointed Interim Chief Medical Officer
- Adaptive Biotechnologies (company) — Dr. Mallon's previous employer
FAQ
Who has been appointed as the new CEO of NeoGenomics, Inc.?
Dr. Mark Mallon has been appointed as the new Chief Executive Officer of NeoGenomics, Inc.
When was the appointment of the new CEO effective?
The appointment of Dr. Mark Mallon as CEO was effective immediately as of April 15, 2024.
Who previously held the CEO position at NeoGenomics, Inc.?
Dr. Jeffrey Miller previously held the CEO position at NeoGenomics, Inc. and has departed the company.
What other executive change was announced by NeoGenomics, Inc.?
Dr. Steven B. Johnson was appointed as the Interim Chief Medical Officer.
What was Dr. Mark Mallon's prior role before joining NeoGenomics?
Dr. Mark Mallon previously served as the Chief Executive Officer of Adaptive Biotechnologies.
Filing Stats: 474 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2024-04-18 07:00:10
Key Financial Figures
- $0.001 — ch registered: Common Stock, par value $0.001 per share NEO The Nasdaq Stock Market L
Filing Documents
- neo-20240415.htm (8-K) — 25KB
- 0001077183-24-000048.txt ( ) — 147KB
- neo-20240415.xsd (EX-101.SCH) — 2KB
- neo-20240415_lab.xml (EX-101.LAB) — 22KB
- neo-20240415_pre.xml (EX-101.PRE) — 13KB
- neo-20240415_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers Election of Directors Appointment of Certain Officers
Item 5.02 Departure of Directors or Certain Officers Election of Directors Appointment of Certain Officers Compensatory Arrangements of Certain Officers. On April 15, 2024, NeoGenomics, Inc., a Nevada corporation (the "Company") announced that as part of the on-going restructuring efforts, the executive position of President, Advanced Diagnostics is being eliminated and as a result, Vishal Sikri, the current President, Advanced Diagnostics, will no longer hold such role and will no longer be a named executive officer. The effective date of the change is still being determined by the Company. Additionally, on April 15, 2024, the Company announced Melody Harris, presently the Company's President, Enterprise Operations will now serve as the Company's Chief Operations Officer and President, Informatics. In addition, Warren Stone, presently the Company's President, Clinical Services will now serve as the Company's Chief Commercial Officer.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOGENOMICS, INC. Date: April 18, 2024 By: /s/ Alicia C. Olivo Alicia C. Olivo EVP, General Counsel & Business Development and Corporate Secretary